Unique ID issued by UMIN | UMIN000049847 |
---|---|
Receipt number | R000056782 |
Scientific Title | Questionnaire survey of patients and physicians for Early-stage hepatocellular carcinoma |
Date of disclosure of the study information | 2022/12/22 |
Last modified on | 2023/09/28 10:11:51 |
Questionnaire survey of patients and physicians for Early-stage hepatocellular carcinoma
Questionnaire survey of patients and physicians for Early-stage hepatocellular carcinoma
Questionnaire survey of patients and physicians for Early-stage hepatocellular carcinoma
Questionnaire survey of patients and physicians for Early-stage hepatocellular carcinoma
Japan |
Hepatocellular carcinoma
Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery |
Malignancy
NO
To clarify the well-being changes and those reasons in patients with hepatocellular carcinoma receiving repeated locoregional therapy (hepatectomy or ablation).
Others
To clarify the important things for patients in locoregional therapy and adjuvant therapy from the views of patients who received locoregional therapy and physicians who performed locoregional therapy, respectively.
Others
Others
Not applicable
Well-being and the factors associated with well-being changes in patients with Early-stage hepatocellular carcinoma
To clarify the important things for patients in locoregional therapy and adjuvant therapy from the views of patients who received locoregional therapy and physicians who performed locoregional therapy, respectively.
Others,meta-analysis etc
20 | years-old | <= |
Not applicable |
Male and Female
Patients
1. Aged less than 20years
2.Residents of Japan who received locoregional therapy for hepatocellular carcinoma (hepatectomy or ablation) more than two times
3.Within 5 years of last locoregional therapy (hepatectomy or ablation)
4.Signed informed consent form
Physicians
1.Licensed Japanese medical doctors who performed an average of at least 5cases/year of hepatectomy or ablation within 5 years
2.At least five cases of hepatectomy or ablation in the last year
3.Signed informed consent form
Patients who are engaged in a pharmaceutical, medical, or survey-related job
200
1st name | Hiroki |
Middle name | |
Last name | Matsumoto |
Ono Pharmaceutical Co., Ltd.
Oncology Medical, Medical Affairs
103-0023
9-11, Nihonbashi-Honcho 4-Chome Chuo-ku, Tokyo
03-5640-3711
hi.matsumoto@ono-pharma.com
1st name | Anri |
Middle name | |
Last name | Watanabe |
3H Clinical Trial Co., Ltd.
Insight & Outcome Group
171-0022
1-13-23,Minamiikebukuro,Toshima-ku, Tokyo,JRE Minamiikebukuro Building 2F
03-5985-0053
a-watanabe@3h-ct.co.jp
Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Bristol-Myers Squibb K.K.
Profit organization
Japan Conference of Clinical Research
1-13-23,Minamiikebukuro,Toshima-ku, Tokyo.
03-6868-7022
jccr-info@jccr.jp
NO
2022 | Year | 12 | Month | 22 | Day |
Unpublished
Completed
2022 | Year | 12 | Month | 01 | Day |
2022 | Year | 12 | Month | 16 | Day |
2022 | Year | 12 | Month | 23 | Day |
2023 | Year | 01 | Month | 16 | Day |
2023 | Year | 01 | Month | 16 | Day |
2023 | Year | 02 | Month | 01 | Day |
2023 | Year | 07 | Month | 26 | Day |
None
2022 | Year | 12 | Month | 21 | Day |
2023 | Year | 09 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056782
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |